Leave No Drug Behind — Universal Reform Framework
Core argument: Drug exceptionalism — treating each drug as requiring its own special reform logic — is analytically incoherent and produces inequitable outcomes. A person with PTSD treated with ketamine (already legal) has better access than a person with PTSD who would benefit from MDMA (still Schedule I). A cannabis user in a legal jurisdiction has fewer legal risks than a psilocybin user in the same jurisdiction. These disparities reflect political palatability, not pharmacological risk or therapeutic benefit.
Universal framework principle: Transform's universal reform framework applies the same analytical criteria — sweet spot between prohibition and free-market commercialisation, five capture-prevention criteria, four-tier access model, five reparative pillars — to every substance. This produces consistent, principled outcomes rather than substance-by-substance political negotiation.
Exceptionalism cost: Every time psychedelic reform advocates argue that psilocybin is 'different' from cannabis — safer, more therapeutic, more deserving of legal access — they are making an exceptionalist argument that strengthens the prohibition of the substances they are not advocating for. Transform's framework is explicitly anti-exceptionalist: the question is not whether a substance is special enough to deserve reform, but whether its current regulatory regime is producing better or worse outcomes than the alternatives.
What Pharmaceutical-Track FDA Approval Means for Tier Access
What approval means: FDA pharmaceutical approval for psilocybin (if Compass COMP360 approved) or MDMA (if Lykos resubmission approved) would mean: (1) The compound can be prescribed by licensed physicians. (2) The patent-holder controls the approved formulation — Polymorph A for psilocybin. (3) Insurance coverage determines access — if not covered, market-rate pricing applies. (4) The non-pharmaceutical supply (Oregon/Colorado facilitated access, personal cultivation) remains legally in tension with federal scheduling even after rescheduling, because the approved pharmaceutical pathway is the one the DEA/FDA will prioritise.
Tier implications: FDA approval of Compass COMP360 would not create Tier 2 or Tier 3 pathways. It would create a Tier 4 equivalent (supervised commercial use) under pharmaceutical rather than facilitated access models. The Oregon/Colorado models would remain as parallel state-level frameworks in legal ambiguity relative to federal pharmaceutical approval.
Who benefits: Market-rate pharmaceutical psychedelic therapy: estimated $10,000-$30,000 per treatment course based on ketamine therapy pricing benchmarks. Without insurance coverage mandates, this is accessible primarily to upper-income patients. The equity gap between pharmaceutical-track access and the communities most harmed by prohibition is the defining inequity of the pharmaceutical approval pathway.
The Four-Tier Regulatory Framework
Score every significant U.S. psychedelic regulatory development against this framework. The question is not what happened but which failure mode is this development pushing toward — and whether it enables, restricts, or forecloses the non-commercial structural alternatives.
Home cultivation, foraging, not-for-profit sharing. Grow, gather, gift. No commercial transaction. No licensing of individuals.
- Automatic and permanent deletion of historic criminal records for personal use and possession
- No confiscation of personal-use quantities
- No licence required for personal cultivation or foraging
- Not-for-profit sharing between adults permitted without restriction
Licensed by centralised drug authority. Non-profit legal structure. No commercial sales. No advertising. Membership-only access. Modelled on Spanish cannabis social clubs.
- Licensed by centralised drug authority — not self-governing
- Non-profit legal structure required — no profit distribution
- No commercial sales to general public
- No advertising or branding
- Membership-only — open membership process but not retail
- Quantity limits per member
- Harm reduction information provided at point of access
State-controlled supply chain with strict public health conditions. No commercial branding. No alcohol/tobacco sector participation. Licence caps mandatory.
- State monopoly or state-licensed supply with tight market concentration limits
- Adult-only access (18+ or 21+)
- Plain white non-branded packaging
- High-visibility health warnings
- Holographic seals for product verification
- Harm-reduction information leaflet with every product
- Advertising, branding, and marketing forbidden beyond functional availability information
- No candy-like infused edibles or products designed to appeal to minors
- Licence caps and market-share limits mandatory
- Riskier preparations (intravenous) restricted or prohibited in initial phase
Trained licensed facilitators. Duty of care. Curbs on false or misleading medical claims. Currently the primary model being pursued in US psychedelic reform.
- Trained and licensed facilitators required
- Duty of care obligations on facilitators
- Curbs on false or misleading therapeutic claims
- Site licensing for service centres/healing centres
- No take-home — supervised use only
What a Green US Psychedelic Framework Would Look Like
No current US psychedelic jurisdiction meets any of the six green criteria above. Oregon and Colorado meet partial elements of Tier 1 and Tier 4. The distance between current frameworks and a Transform-aligned green framework is the measure of what advocacy, legislation, and regulatory design work remains.
Scored Developments
MCDA regime: Between Regime 2 and Regime 4
Progressive first step but structurally incomplete. Supervised commercial model without non-commercial alternative means all access flows through licensed commercial operators. Equity provisions weak relative to cannabis comparators.
MCDA regime: Regime 2 (personal) + between Regime 2 and Regime 4 (supervised)
More progressive than Oregon on Tier 1 (personal use and gifting permitted). Still no Tier 2 pathway. Peyote excluded by name (correct) but synthetic mescaline included (Indigenous knowledge concern).
MCDA regime: Maintains Regime 1 for MDMA
FDA rejected Lykos NDA citing clinical trial data quality concerns and requested additional Phase 3 study. From a Transform framework perspective: delay in pharmaceutical-track approval preserves the window for non-commercial access frameworks to be established first. Monitor for whether this window is used to develop Tier 2 or Tier 3 alternatives.
MCDA regime: Would move from Regime 1 toward Regime 4 if pharmaceutical approval follows
Rescheduling to Schedule III would allow prescription use and facilitate FDA approval pathway for Compass COMP360. Does not by itself create non-commercial or equity access. The window between rescheduling and FDA approval is the critical period for establishing Tier 2 and Tier 3 frameworks.
Four MCDA Regimes
Current federal status for psilocybin, DMT, MDMA, ibogaine, mescaline (except peyote for NAC members). Zero legal access. All use criminalised.
Federal prohibition persists despite state-level reform. DEA scheduling is the primary legal mechanism. Rescheduling requires either DEA administrative action or congressional legislation.
Personal possession and use decriminalised. No legal supply. Users no longer criminalised but must obtain from illegal market.
Oregon Measure 110 (decriminalisation, now repealed), Washington DC Initiative 81, Colorado Prop 122 personal use provisions. Decriminalisation without legal supply does not address production, distribution, or quality control harms.
State-controlled supply with public health conditions. Alberta cannabis (15% cap) is the closest approximation in any drug market globally.
MCDA modelling identifies this as the preferred regime across alcohol, cannabis, and heroin. No psychedelic jurisdiction has reached this regime. The pharmaceutical-track is explicitly NOT this regime — patent holders, not the state, control supply.
Patent-holder controlled supply, market-rate pricing, pharmaceutical-sector consolidation.
FDA pharmaceutical approval track for psilocybin (Compass) or MDMA (Lykos) would produce this regime by default — no price controls, no market concentration limits, no non-commercial access alternatives unless explicitly legislated alongside approval.
Key Fixed Vocabulary
The current trajectory, scored against Transform’s four-tier framework: Tier 1 partially operationalised (Colorado personal use), Tier 4 operationalised (Oregon and Colorado supervised commercial), Tier 2 and Tier 3 completely unaddressed in every US jurisdiction. This is not a neutral omission. The Leave No Drug Behind framework makes explicit that exceptionalist arguments — treating psilocybin as deserving of special supervised-only access — reproduce the structural gaps that benefit well-capitalised pharmaceutical actors and exclude communities most harmed by prohibition.
The pharmaceutical approval mechanics section clarifies what FDA approval actually means for tier access: a patent-holder controlled supply at market-rate pricing with no legal requirement for non-commercial alternatives. The green framework template provides the specific criteria — six dimensions, none of which any current US framework meets. The distance between where the sector is and where Transform’s framework says it needs to be is the measure of the work remaining.
The Alberta cannabis 15% licence cap and Uruguay’s combined Tier 1+2+3 model are the closest global approximations to Transform’s sweet spot in any drug market. No psychedelic jurisdiction comes close. The FDA rejection of the Lykos MDMA NDA (August 2024) created a window — pharmaceutical-track approval has been delayed. Whether that window is used to establish Tier 2 and Tier 3 frameworks before Lykos resubmits is the critical development this tab monitors.
Subscribe to Psychedelic Commercialisation Index alerts
Receive the Monday 8am HST weekly intelligence digest when new developments are scored for this tab.
We store only the name and email you enter here, and use them only to send this digest. Every email carries an unsubscribe link, which removes the address immediately.